Basit öğe kaydını göster

dc.contributor.authorDerbentli, Sengul
dc.contributor.authorAktas, Gülseren
dc.date.accessioned2021-03-04T08:32:34Z
dc.date.available2021-03-04T08:32:34Z
dc.date.issued2017
dc.identifier.citationAktas G., Derbentli S., "In vitro activity of daptomycin combined with dalbavancin and linezolid, and dalbavancin with linezolid against MRSA strains", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, cilt.72, sa.2, ss.441-443, 2017
dc.identifier.issn0305-7453
dc.identifier.otherav_63d15539-37a8-41a0-a602-99e1a350bdd5
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/69484
dc.identifier.urihttps://doi.org/10.1093/jac/dkw416
dc.description.abstractObjectives: Combination therapies have a distinct advantage over monotherapies in terms of their broad spectrum, synergistic effect and prevention of the emergence of drug resistance. In the present study, the in vitro antibacterial activity of daptomycin combinations with linezolid and dalbavancin, and dalbavancin with linezolid were evaluated against 30 clinical MRSA strains.
dc.language.isoeng
dc.subjectTemel Eczacılık Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectEczacılık
dc.subjectSağlık Bilimleri
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectMikrobiyoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectİmmünoloji
dc.subjectBULAŞICI HASTALIKLAR
dc.titleIn vitro activity of daptomycin combined with dalbavancin and linezolid, and dalbavancin with linezolid against MRSA strains
dc.typeMakale
dc.relation.journalJOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume72
dc.identifier.issue2
dc.identifier.startpage441
dc.identifier.endpage443
dc.contributor.firstauthorID97052


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster